Table 1.
Assessment of the ability of different human antibodies to block each other's binding to immobilized Phl p 5
| Inhibitory scFv–Fcγ2 | Test clone (scFv–Fcε) | Inhibitory scFv–Fcε | Test clone (scFv–Fcγ2) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4.3 | 4.4 | 4.13 | 4.12 | p5-AB5 | p5-MA5 | p6-12 | clone 5 | ||
| 4.3 | ++ | − | − | − | − | − | 4.3 | ++ | − |
| Clone 5 | − | − | − | − | − | − | Clone 5 | nd | nd |
| 4.4 | − | + | + | − | − | − | 4.4 | − | − |
| 4.13 | − | ++ | ++ | + | − | − | 4.13 | − | − |
| 4.12 | − | − | − | + | − | + | 4.12 | − | − |
| p5-AB5 | − | − | − | ++ | + | ++ | p5-AB5 | − | − |
| p5-MA5 | − | ++ | − | ++ | − | ++ | p5-MA5 | − | − |
++: > 80% inhibition; +: 50–80% inhibition; −: < 50% inhibition.
nd, not determined as clone 5 (and p6-12) scFv–Fcε could not be produced.